In June 2020, Monopar entered into a collaboration with NorthStar Medical Radioisotopes, LLC, to develop potential Radio-Immuno-Therapeutics (RITs) to treat severe COVID-19 (patients with SARS-CoV-2 infection), coupling MNPR-101 to therapeutic radioisotopes supplied by NorthStar. This collaboration combines NorthStar’s expertise in the innovative production, supply, and distribution of important medical radioisotopes with Monopar's expertise in therapeutic drug development.

NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging and therapeutic purposes.